Novartis, a leader in the
biotech market, has been facing significant fluctuations. The share price has shown an appreciable amount of strength and the
stock has gained due to reports of a
White House pricing deal. Several investment firms, like Osaic Holdings, Wellington Capital Management, and Lavaca Capital have significantly increased their stock holdings, indicating trust and support of Novartis' strategic moves. The company's shares, even after rising by 17.5%, seem to remain attractive, sparking debates within investors. Despite falling
value due to generics affecting its blockbuster heart drug, Morgan Stanley upgraded Novartis following a stock pullback and Rhapsido product launch. Notably, Novartis has made remarkable progress in its pipeline, especially with the acquisition of U.S. biotech firm
Avidity Biosciences for around $12 billion and the anticipated launch of the first gene therapy for muscle-weakening disorder. As a result, long-term value and momentum holders consider Novartis a top stock. However, Goldman Sachs advises caution, suggesting the stock might be overvalued.
Novartis Stocks News Analytics from Wed, 25 Jun 2025 07:00:00 GMT to Sat, 20 Dec 2025 07:31:30 GMT -
Rating 6
- Innovation 4
- Information 7
- Rumor -2
